Tailoring antiviral therapy in hepatitis C
Open Access
- 20 April 2006
- journal article
- editorial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 43 (5) , 909-911
- https://doi.org/10.1002/hep.21194
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapyHepatology, 2006
- Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaJournal of Hepatology, 2005
- Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis CGastroenterology, 2005
- Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3New England Journal of Medicine, 2005
- Treatment With Pegylated Interferon and Ribavarin in Hcv Infection With Genotype 2 Or 3 for 14 Weeks: A Pilot StudyHepatology, 2004
- Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis CHepatology, 2003
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998
- Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA.Gut, 1995
- Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis CAnnals of Internal Medicine, 1991
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989